News
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.
The art of talking about risks with our patients
On the first day of EULAR 2024, I am debating Janet Pope.
Humira Clobbers Biosimilars in Battle for Part D Coverage
Medpage Today
Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Cannabis Use is Common, But is it Safe?
Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.
Molecular Profile for Cardiovascular Risk in Rheumatoid Arthritis
A new study led by the University of Córdoba, the Maimonides Institute for Biomedical Research and the Rheumatology Department at the Reina Sofía University Hospital in Córdoba has managed to establish, for the first time, the molecular profile of those patients with rheumatoid arthritis who have a higher risk of suffering cardiovascular events.
JAK or TNF Inhibitor as First Drug for Rheumatoid Arthritis?
Medpage Today
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs had failed, a pragmatic head-to-head trial found.
2023 EULAR classification criteria for hand osteoarthritis
A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).
The criteria require two mandatory criteria to be met:
ACR Calls on CMS for Enhanced Transparency & Reporting
The American College of Rheumatology has submitted its response to the Centers for Medicare & Medicaid Services (CMS) request for information and feedback from stakeholders on how best to enhance Medicare Advantage data capabilities and increase public transparency.
Role of Diet in Gout Risk
Diet has long been influential in gout care and risks. A large cohort study has shown that plant-based diets may reduce the risk of developing gout. This prospective study assessed the risk of developing incident gout based on consumption of healthy and unhealthy plant-based diets.
